Beijing Tong Ren Tang Chinese Medicine Co (TQR) Ratios
Beijing Tong Ren Tang Chinese Medicine Co Ratios
DE:TQR's free cash flow for Q2 2026 was $293.50M. For the 2026 fiscal year, DE:TQR's free cash flow was decreased by $-2.62M and operating cash flow was $296.12M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 19.65 | 16.85 | 11.65 | 8.80 | 15.38 |
| Quick Ratio | 13.16 | 10.10 | 8.59 | 7.68 | 13.35 |
| Cash Ratio | 10.77 | 7.53 | 3.03 | 4.76 | 7.79 |
| Solvency Ratio | 1.70 | 1.88 | 1.51 | 1.48 | 2.29 |
| Operating Cash Flow Ratio | 4.20 | -0.92 | 1.40 | 1.31 | 3.65 |
| Short-Term Operating Cash Flow Coverage | 12228.65 | -3059.87 | 2776.09 | 2499.74 | 1619.10 |
| Net Current Asset Value | $ 3.77B | $ 3.65B | $ 3.43B | $ 3.20B | $ 2.98B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.03 | 0.03 | 0.03 | 0.02 | 0.03 |
| Debt-to-Equity Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Debt-to-Capital Ratio | 0.03 | 0.03 | 0.03 | 0.03 | 0.04 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.11 | 1.12 | 1.15 | 1.17 | 1.12 |
| Debt Service Coverage Ratio | 84.89 | 94.89 | 111.06 | 158.39 | 139.96 |
| Interest Coverage Ratio | 83.43 | 89.02 | 104.41 | 174.12 | 165.38 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.16 | 0.16 | 0.16 | 0.13 | 0.16 |
| Net Debt to EBITDA | -3.66 | -2.28 | -1.11 | -2.08 | -1.80 |
| Profitability Margins | |||||
| Gross Profit Margin | 61.16% | 66.10% | 68.67% | 66.44% | 71.95% |
| EBIT Margin | 31.45% | 39.48% | 45.49% | 47.98% | 50.32% |
| EBITDA Margin | 37.95% | 44.82% | 51.12% | 52.43% | 54.80% |
| Operating Profit Margin | 31.20% | 35.80% | 40.93% | 46.88% | 50.02% |
| Pretax Profit Margin | 33.35% | 39.08% | 45.10% | 47.71% | 50.02% |
| Net Profit Margin | 26.25% | 31.04% | 35.44% | 37.31% | 39.06% |
| Continuous Operations Profit Margin | 27.55% | 32.83% | 38.73% | 40.02% | 41.85% |
| Net Income Per EBT | 78.71% | 79.44% | 78.57% | 78.20% | 78.09% |
| EBT Per EBIT | 106.87% | 109.16% | 110.20% | 101.77% | 99.99% |
| Return on Assets (ROA) | 8.52% | 10.97% | 12.19% | 15.29% | 15.85% |
| Return on Equity (ROE) | 9.48% | 12.28% | 13.98% | 17.92% | 17.78% |
| Return on Capital Employed (ROCE) | 10.60% | 13.34% | 15.21% | 21.32% | 21.49% |
| Return on Invested Capital (ROIC) | 8.66% | 11.06% | 12.88% | 17.65% | 17.73% |
| Return on Tangible Assets | 8.64% | 11.14% | 12.34% | 15.51% | 16.11% |
| Earnings Yield | 5.61% | 6.81% | 5.25% | 6.73% | 5.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 3.62 | 3.06 | 3.61 | 1.84 | 2.95 |
| Payables Turnover | 9.48 | 14.25 | 2.70 | 3.78 | 12.62 |
| Inventory Turnover | 0.44 | 0.34 | 0.47 | 1.24 | 1.01 |
| Fixed Asset Turnover | 3.36 | 3.91 | 3.49 | 4.27 | 3.78 |
| Asset Turnover | 0.32 | 0.35 | 0.34 | 0.41 | 0.41 |
| Working Capital Turnover Ratio | 0.40 | 0.44 | 0.45 | 0.55 | 0.54 |
| Cash Conversion Cycle | 895.31 | 1155.15 | 739.00 | 397.20 | 455.88 |
| Days of Sales Outstanding | 100.71 | 119.13 | 101.24 | 198.62 | 123.71 |
| Days of Inventory Outstanding | 833.13 | 1061.64 | 772.98 | 295.15 | 361.10 |
| Days of Payables Outstanding | 38.52 | 25.62 | 135.22 | 96.57 | 28.93 |
| Operating Cycle | 933.83 | 1180.77 | 874.22 | 493.77 | 484.81 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1.04 | -0.26 | 0.55 | 0.65 | 0.93 |
| Free Cash Flow Per Share | 0.99 | -0.31 | 0.52 | 0.61 | 0.90 |
| Dividend Paid and CapEx Coverage Ratio | 2.60 | -0.68 | 1.55 | 1.14 | 3.46 |
| Capital Expenditure Coverage Ratio | 21.08 | -5.03 | 21.08 | 14.22 | 33.17 |
| Operating Cash Flow Coverage Ratio | 6.86 | -1.76 | 3.50 | 5.31 | 6.05 |
| Operating Cash Flow to Sales Ratio | 0.57 | -0.13 | 0.30 | 0.32 | 0.50 |
| Free Cash Flow Yield | 11.68% | -3.54% | 4.26% | 5.31% | 6.71% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 18.00 | 14.69 | 19.05 | 14.85 | 18.48 |
| Price-to-Sales (P/S) Ratio | 4.68 | 4.56 | 6.75 | 5.54 | 7.22 |
| Price-to-Book (P/B) Ratio | 1.69 | 1.80 | 2.66 | 2.66 | 3.29 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 8.56 | -28.22 | 23.46 | 18.85 | 14.90 |
| Price-to-Operating Cash Flow Ratio | 8.16 | -33.83 | 22.34 | 17.52 | 14.45 |
| Price-to-Earnings Growth (PEG) Ratio | -0.83 | -1.91 | -1.22 | 2.71 | 1.50 |
| Enterprise Value Multiple | 8.67 | 7.89 | 12.09 | 8.49 | 11.38 |
| Enterprise Value | 4.98B | 5.70B | 9.43B | 7.71B | 9.70B |
| EV to EBITDA | 8.67 | 7.89 | 12.09 | 8.49 | 11.38 |
| EV to Sales | 3.29 | 3.54 | 6.18 | 4.45 | 6.23 |
| EV to Free Cash Flow | 6.02 | -21.89 | 21.48 | 15.14 | 12.87 |
| EV to Operating Cash Flow | 5.74 | -26.24 | 20.46 | 14.08 | 12.48 |
| Tangible Book Value Per Share | 5.14 | 4.99 | 4.74 | 4.40 | 4.16 |
| Shareholders’ Equity Per Share | 5.00 | 4.87 | 4.62 | 4.31 | 4.08 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.17 | 0.16 | 0.14 | 0.16 | 0.16 |
| Revenue Per Share | 1.81 | 1.93 | 1.82 | 2.07 | 1.86 |
| Net Income Per Share | 0.47 | 0.60 | 0.65 | 0.77 | 0.73 |
| Tax Burden | 0.79 | 0.79 | 0.79 | 0.78 | 0.78 |
| Interest Burden | 1.06 | 0.99 | 0.99 | 0.99 | 0.99 |
| Research & Development to Revenue | 0.01 | 0.01 | 0.01 | 0.00 | 0.01 |
| SG&A to Revenue | 0.26 | 0.31 | 0.12 | 0.09 | 0.10 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 2.19 | -0.34 | 0.85 | 0.66 | 1.00 |
Currency in HKD